Clinical Significance of Plasma and Peripheral Blood Mononuclear Cell EBV ‐ DNA in Lymphoma
Journal of Clinical Laboratory Analysis · 2025-09 · 39 (18)
DOI: 10.1002/jcla.70092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 13.08.2025. Verfasst von Lu Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospi…. Hauptthemen laut MEDLINE: DNA, Viral, Herpesvirus 4, Human, Leukocytes, Mononuclear, Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Epstein Barr virus (EBV) is a ubiquitous virus that establishes latent infection in the host and plays a critical role in the development and prognosis of lymphomas. The presence of EBV‐DNA in peripheral blood is a widely used tumor marker. However, there is no consensus on the preferred blood compartment for EBV‐DNA testing.
Methods
We retrospectively analyzed data from 256 lymphoma patients, including 21 with Hodgkin lymphoma, 96 with B‐cell lymphoma, and 139 with T‐cell or NK/T‐cell lymphoma. Complete matched PBMC and plasma EBV‐DNA datasets were available, allowing correlation analysis and assessment of their respective clinical significance.
Results
Detectable pretreatment EBV‐DNA in either plasma or PBMCs was significantly associated with worse survival outcomes ( p < 0.001), with the worst prognosis observed in patients positive in both compartments. Longitudinal monitoring demonstrated that patients with negative EBV‐DNA or declining viral loads in PBMCs or plasma had significantly improved progression‐free survival compared to those with persistent positivity or increasing copy numbers ( p < 0.001). Notably, changes in plasma EBV‐DNA levels showed higher accuracy than PBMC EBV‐DNA in reflecting treatment response. Multivariate analysis identified PBMC EBV‐DNA positivity as an independent prognostic factor for inferior OS ( p = 0.031) and PFS ( p = 0.003).
Conclusion
Both plasma and PBMC EBV‐DNA are valuable for prognostic evaluation in lymphoma patients. Plasma EBV‐DNA demonstrates superior utility for monitoring treatment response, whereas PBMC EBV‐DNA provides stronger prognostic information. Selection of the appropriate sample type should be tailored to the clinical context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, China.
ORCID-Profile: Lu Wang, Qingyun Zhang
Zitieren
APA
Wang, L., Xu, G., Xu, J., & Zhang, Q. (2025). Clinical Significance of Plasma and Peripheral Blood Mononuclear Cell EBV ‐ DNA in Lymphoma. Journal of Clinical Laboratory Analysis, 39(18). https://doi.org/10.1002/jcla.70092
Vancouver
Wang L, Xu G, Xu J, Zhang Q. Clinical Significance of Plasma and Peripheral Blood Mononuclear Cell EBV ‐ DNA in Lymphoma. Journal of Clinical Laboratory Analysis. 2025;39(18). doi:10.1002/jcla.70092
BibTeX
@article{Wang2025,
author = {Wang, Lu and Xu, Guobing and Xu, Jianjun and Zhang, Qingyun},
title = {Clinical Significance of Plasma and Peripheral Blood Mononuclear Cell EBV ‐ DNA in Lymphoma},
journal = {Journal of Clinical Laboratory Analysis},
year = {2025},
volume = {39},
number = {18},
doi = {10.1002/jcla.70092}
}
EUVIMED